The Trademark Trial and Appeal Board (TTAB) has issued a decision sustaining an opposition filed by Thermo Fisher Scientific against Qubit Pharmaceuticals. The opposition concerned the registration of the mark 'QUBIT PHARMACEUTICALS'. This ruling effectively prevents Qubit Pharmaceuticals from registering this mark, based on the findings of the TTAB.

This decision has direct implications for Qubit Pharmaceuticals' brand strategy and trademark portfolio. The company must cease any efforts to register the contested mark and may need to re-evaluate its branding to avoid further intellectual property disputes. Thermo Fisher Scientific has successfully defended its existing trademark rights.